
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clazakizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : CSL
Deal Size : Undisclosed
Deal Type : Acquisition
CSL Behring to Acquire Biotech Company Vitaeris
Details : With this acquisition, clazakizumab joins CSL842 and CSL964 as part of CSL Behring’s portfolio of products in late-stage development to address significant unmet needs in the transplant community.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 08, 2020
Lead Product(s) : Clazakizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : CSL
Deal Size : Undisclosed
Deal Type : Acquisition
